Utilization of vasculoprotective therapy for peripheral artery disease: a systematic review and meta-analysis
DG Hackam, MV Vyas - The American Journal of Medicine, 2018 - Elsevier
Introduction Practice guidelines recommend that patients with peripheral artery disease
receive antiplatelets, statins, and angiotensin-converting enzyme (ACE) inhibitors or …
receive antiplatelets, statins, and angiotensin-converting enzyme (ACE) inhibitors or …
Utilization of Vasculoprotective Therapy for Peripheral Artery Disease: A Systematic Review and Meta-analysis
DG Hackam, MV Vyas - The American Journal of Medicine, 2018 - amjmed.com
Introduction Practice guidelines recommend that patients with peripheral artery disease
receive antiplatelets, statins, and angiotensin-converting enzyme (ACE) inhibitors or …
receive antiplatelets, statins, and angiotensin-converting enzyme (ACE) inhibitors or …
Utilization of Vasculoprotective Therapy for Peripheral Artery Disease: A Systematic Review and Meta-analysis
DG Hackam, MV Vyas - The American journal of medicine, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction Practice guidelines recommend that patients with peripheral artery disease
receive antiplatelets, statins, and angiotensin-converting enzyme (ACE) inhibitors or …
receive antiplatelets, statins, and angiotensin-converting enzyme (ACE) inhibitors or …
Utilization of Vasculoprotective Therapy for Peripheral Artery Disease: A Systematic Review and Meta-analysis.
DG Hackam, MV Vyas - The American Journal of Medicine, 2018 - europepmc.org
Methods We performed a systematic review and meta-analysis of treatment prescribing rates
in observational studies containing peripheral artery disease patients published on or after …
in observational studies containing peripheral artery disease patients published on or after …